Laboratory findings and follow-up information in patients with COVID-19 who underwent kidney biopsy
| Pt | Baseline sCr | Renal Function at Presentation | Complete Blood Counts | Other Laboratory Tests | Follow-Up Information | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sCr | Dialysis | Urine Prot | sAlb | Urine RBC | Hgb | WBC | Plt | Duration, d | Therapy | Outcome | |||
| 1 | 1.1 | 12.5 | Y | 5.8 | 3.1 | 2 | 16.6 | 7.7 | 242 | LDH 1504 U/L, ESR>130 mm/h, hsCRP 49.4 mg/L ferritin 1147 ng/ml, IL-6 12 pg/ml, IL-2R 1530 pg/ml | 24 | Tocilizumab, steroids | Dialysis dependent with sCr 14.2 mg/dl, UPCR 10.2 g/g, repeat COVID-19 negative |
| 2 | 2 | 10.7 | N | 12.1 | 3.1 | 0–5 | 14.2 | 7.1 (with lymphopenia) | 235 | ESR 125 mm/h, ferritin 340.3 ng/ml | 30 | None | sCr 3.8 mg/dl, UACR 5.5 g/g, repeat COVID-19 negative |
| 3 | 1 | 11.6 | N | 19 | 2.4 | 11.7 | 14.4 (with lymphopenia) | 355 | ESR 130 mm/h, CRP 232 mg/L, ferritin 5000 ng/ml | 12 | Steroids, hydroxychloroquine, ceftriaxone, doxycycline | sCr 2.3 mg/dl, UPCR 4 g/g, decreased ferritin, ESR, IL-6 | |
| 4 | 1.1 | 4.9 | N | 6.2 | 2.5 | 0 | 9.8 | 7 | 257 | elevated ESR, CRP 11.1 mg/L, ferritin 907 ng/ml, elevated IL-6 and d-dimer, CK 3200 U/L, +HCV Ab | 11 | Azithromycin, ceftriaxone | sCr 4.9 mg/dl, UPCR 4.1 g/g, repeat COVID-19 negative |
| 5 | Normal | 15 | Y | 9 | 2.5 | 8.3 | 21 | 368 | ESR 41 mm/h, CRP 229 mg/L, ferritin 2542 ng/ml | 5 | Dialysis dependent, repeat COVID-19 negative | ||
| 6 | Normal | 2.2 | N | 21 | <1.5 | 3–5 | 13.9 | 8.5 | 408 | LDH 590 U/L, CRP 33.4 mg/L, ferritin 374 ng/ml | 27 | Azithromycin, hydroxychloroquine, steroids | sCr 0.8 mg/dl, UPCR 4.3 g/g, decreased CRP |
| 7 | 3.5 (at adm) | 6.7 | Y | 1+ on UA | 21–50 | 11.4 | 14 | 250 | None | ||||
| 8 | 2 (at adm) | 9 | Y | 100 mg/dl on UA | 2.6 | 0 | 10.6 | 13.1 (with lymphopenia) | 320 | LDH 3075 U/L, CRP 4.7 mg/L, ferritin >7500 ng/ml, CK 3309 U/L | <30 | Tocilizumab, hydroxychloroquine, ceftriaxone, azithromycin | sCr 1.2 mg/dl |
| 9 | 5.7 | Y | 300 mg/dl on UA | 2.7 | >5 | 12.8 | 9.2 (with lymphopenia) | 454 | LDH 309 U/L, CRP 13 mg/L, ESR>100 mm/h, ferritin 924 ng/ml, CK 128 U/L | 30 | Tocilizumab, hydroxychloroquine, ceftriaxone, azithromycin | Dialysis dependent | |
| 10 | 1.5–1.8 | 4.8 | N | 0.5 | 4.2 | 3 | 11.5 | 3.2 | 107 | LDH 524 U/L, CRP 50.8 mg/L, ESR 33 mm/h, ferritin 2282 ng/ml, IL-6 21.4 pg/ml, +ANA | 1 | Hydroxychloroquine | sCr 2.5 mg/dl, urine prot 100 mg/dl on UA, repeat COVID-19 positive |
| 11 | Normal | 0.8 | N | 8.8 | 1.7 | 6–15 | 12.3 | 14.8 | 283 | LDH 300 U/L, CRP 153 mg/L, ferritin 397 ng/ml | 18 | Tacrolimus | sCr 1.3 mg/dl, repeat COVID-19 positive |
| 12 | 2.9 | N | 6.8 | 3.0 | Present | 9 | 6.1 | 183 | LDH 1019 U/L, ESR 127 mm/h, ferritin 635 ng/ml, +ANA, +anti-dsDNA Ab | 35 | None | sCr 2.4 mg/dl, UPCR 5–6 g/g, improved edema | |
| 13 | 0.9 | 2.5 | N | 9.2 | 2.0 | 20–50 | 8 | 6.8 | 182 | IL-6 79 pg/ml | 6 | Steroids | Died from multiorgan failure secondary to COVID-19 |
| 14 | 0.9 | 20 | Y | >300 mg/dl on UA | 3.1 | >182, with RBC casts | 9.5 | 9.1 | 167 | CRP 143 mg/L, CK 1460 U/L, +anti-GBM Ab | 16 | PLEX, steroids, cyclophosphamide | Dialysis dependent with sCr 6.7 mg/dl, repeat COVID-19 negative |
| 15 | 1.7 | 2.6 | N | 0.2 | 4.5 | 60 | 8.1 | 3.9 | 211 | IL-6 6.6 pg/ml | 55 | Tocilizumab, IVIG, steroids, thymoglobulin | sCr 2 mg/dl, UPCR 0.1 g/g, repeat COVID-19 negative |
| 16 | Dialysis dependent | 9.4 | Y | 3.4 | 4.4 | 6.1 | 202 | LDH 333 U/L, ESR 79 mm/h, CRP 195.6 mg/L, ferritin 1630 ng/ml | 4 | Tocilizumab, hydroxychloroquine, piperacillin-tazobactam, azithromycin | Dialysis dependent with sCr 6.7 mg/dl | ||
| 17 | 2.5 | 2.9 | N | 0.2 | 4.4 | 3 | 10.1 | 3.3 | 286 | CRP 0.49 ng/ml, ferritin 1677 ng/ml (previously) | 7 | None | sCr 2.2 mg/dl |
Pt, patient; sCr, serum creatinine (milligrams per deciliter); urine prot, urine protein-creatinine ratio or 24-h urine protein; sAlb, serum albumin (grams per deciliter); RBC, red blood cell (per high-power field); Hgb, hemoglobin (grams per deciliter); WBC, white blood cell count (103 per microliter); Plt, platelet (103 per microliter); Y, yes; LDH, lactate dehydrogenase; ESR, erythrocyte sedimentation rate; hsCRP, high-sensitivity C-reactive protein; IL-2R, IL-2 receptor; UPCR, urine protein-creatinine ratio; repeat COVID-19, repeat PCR testing for severe acute respiratory syndrome coronavirus 2; N, no; UACR, urine microalbumin-creatinine ratio; CRP, C-reactive protein; CK, creatine kinase; +, positive; HCV Ab, Ab for hepatitis C virus; adm, admission; UA, urinalysis; ANA, antinuclear antibody; dsDNA, double-stranded DNA; PLEX, plasmapheresis; IVIG, intravenous Ig.